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Mini-Abstract 
MACC1 mRNA expression level is a new easily detectable prognostic biomarker in cancer. 
In this work we demonstrated, for the first time, that MACC1 expression, measured on liver 
metastasis specimens, is an independent prognostic factor of recurrence after curative 
resection of colorectal liver metastases.  
 
Structured Abstract 
Objective: upon colon cancer metastasectomy in liver, disease outcome is heterogeneous, 
ranging from indolent to very aggressive, with early recurrence. The aim of this study is to 
investigate the capability of metastasis associated in colon cancer1 (MACC1) levels 
measured in liver metastasis specimens to predict further recurrence of the disease. 
Methods: gene expression and gene dosage of MACC1, hepatocyte growth factor (HGF) 
and hepatocyte growth factor receptor (MET) were assessed using quantitative realtime PCR 
on a cohort of 64 liver metastasis samples from patients with complete follow-up of 36 
months and detailed clinical annotation. The most relevant mutations associated to prognosis 
in colorectal cancer, KRAS and PIK3CA, were assessed on the same specimens with Sanger 
sequencing.  
Results: receiver operating characteristic (ROC) analysis revealed that MACC1 mRNA 
abundance is a good indicator of metastatic recurrence (AUC=0.65, p < 0.05), while no such 
results were obtained with MET and HGF nor with gene dosage. Generation of MACC1-
based risk classes was capable of successfully separating patients into poor and good 
prognosis subgroups (HR = 5.236, 95% CI = 1.2068-22.715, p < 0.05). Also KRAS 
mutation was significantly associated with higher risk of recurrence (HR = 2.07, 95% CI = 
1.048-4.09, p < 0.05) Cox regression multivariate analysis supported the independence of 
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MACC1, but not KRAS, from known prognostic clinical information (Node Size HR = 
3.155, 95% CI = 1.4418-6.905, p < 0.001, Preoperative CEA HR = 2.359, 95% CI = 1.0203-
5.452, p < 0.05, MACC1 HR = 7.2739, 95% CI = 1.6584-31.905, p < 0.01). 
Conclusions: MACC1, a new easily detectable biomarker in cancer, is an independent 
prognostic factor of recurrence after liver resection of colorectal cancer metastasis.  
 
Introduction 
Liver metastases are observed in up to 50% of the more than 1 million patients diagnosed 
with colorectal cancer worldwide every year. If feasible, resection of hepatic lesions is the 
only potentially curative therapy, resulting in 3-year survival rates of up to 60%1, 2. 
Nevertheless, tumor recurrence after curative resection remains a major problem, usually 
occurring within the first 3 years after surgery3. The use of perioperative chemotherapy 
seems to achieve an approximate 8-10% increase in disease-free survival (DFS) rates at 3 
years4-6. Recently, a european expert panel has recommended that most patients with 
resectable colorectal liver metastases should receive perioperative chemotherapy4. However, 
despite a slight increase in DFS, chemotherapy also have toxic effects, either systemic or 
“locoregional” (liver damage) 4, 5. 
Clinical prognostic factors of recurrence have been used to select patients to perioperative 
chemotherapy and to surgery, but they demonstrated a poor predictive value in terms of long 
term outcome7. In an attempt to derive more robust prognostic information, some authors 
have combined multiple clinical prognostic factors to formulate multiparametric scoring 
systems. The first scoring system for patients with colorectal liver metastases was 
introduced in 1996 by Nordlinger et al, subsequently followed in 1999 by Iwatsuki et al and 
by Fong et al8-10. Despite promising predictive value in training datasets, all the proposed 
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scoring systems demonstrated limited external validation  and their clinical utility remains 
controversial11, 12.  
Indeed, molecular biomarkers are expected to better stratify patients with colorectal liver 
metastases beyond what the clinical prognostic factors and scoring systems may offer13. 
Among them, the metastasis-associated in colon cancer-1 (MACC1) gene has promising 
features: it is frequently overexpressed in metastatic colon cancer, and its levels of 
expression in the primary lesion are associated with poor prognosis14-18. These observations 
have been extended also to other cancer types, including lung adenocarcinomas17, 19, 20, 
hepatocellular and gastric carcinomas21-24, and ovarian tumors25, 26. From the biological 
point of view, the above studies pinpoint a role for MACC1 in promoting tumor cell motility 
and invasion, which would then lead to locoregional and systemic dissemination of the 
disease. This hypothesis is supported by mechanistic data demonstrating that MACC1 can 
promote an invasive growth program driven by the HGF-Met signaling axis14, 18, 27, 28. Based 
on these findings, a robust rationale emerges clearly, implicating MACC1 and possibly the 
downstream HGF/Met axis, in the progression of primary tumors toward metastases. 
MACC1 mRNA is expressed both in primary colon cancer and in colon cancer metastases. 
However, to our knowledge, no studies have analyzed the prognostic impact of MACC1 
mRNA expression in tissue specimens of colorectal liver metastases.   
Aim of the present study is to determine the prognostic relevance of MACC1, HGF and 
MET gene dosage and mRNA expression levels on recurrence-free survival in patients 
undergoing curative liver resection for colorectal liver metastases. 
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Materials and Methods 
 
Between October 2008 and March 2010, 113 patients underwent curative liver resection for 
colorectal metastases at the Department of Surgical Oncology of the Institute for the 
Research and Cure of Cancer (IRCC, Candiolo, Turin, Italy) and at the Hepato-bilio-
pancreatic surgical department of the Mauriziano “Umberto I” Hospital (Turin, Italy). Of 
these 113 patients, 64 who had complete molecular and clinical data represent the object of 
the present study.  
Preoperative work-up and Selection criteria for surgery 
Measurement of carcinoembryonic antigen levels (CEA), contrast-enhanced triple-phase 
computed tomography of the thorax and abdomen CT), and magnetic resonance imaging 
with mangafodipir trisodium (MRI) were performed routinely for preoperative staging. 18F-
fluorodeoxyglucose positron emission tomography was used in selected patients. Response 
to neoadjuvant chemotherapy was assessed by CT and MRI according to RECIST criteria29.  
The indocyanine green retention test was routinely performed before surgery to assess liver 
function. Intraoperative ultrasonography was routinely performed. 
Patients were considered candidates for liver resection if all liver metastases were 
technically resectable with curative intent30. Presence of extra-hepatic disease amenable to 
radical surgery was not considered a contraindication to resection.   
Neoadjuvant chemotherapy was performed in patients with initially un-resectable 
hepatic/extra-hepatic metastases. All patients were periodically reviewed by a 
multidisciplinary team (hepato-biliary surgeon, oncologist, and radiologist). Liver surgery 
was performed as soon as metastases became technically resectable.  
Adjuvant chemotherapy was not performed routinely but was based on performance status, 
prognostic factors, and on the number and toxicity of neoadjuvant chemotherapy courses. 
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Follow-up 
Patients underwent abdominal ultrasonography and measurement of serum CEA levels 
every 4 months during the first 2 years and every 6 months thereafter. CT of the chest and 
abdomen was scheduled yearly or carried out whenever a recurrence was suspected.  Disease 
free survival was evaluated on first metastatic relapse after liver metastasectomy, thus we 
defined as good prognosis the patients with DFS greater than 36 months. 
Analyte extraction 
Nucleic acids were isolated from surgically resected colorectal cancer liver metastases and 
from matched normal liver tissues, following overnight incubation of the fresh specimens in 
RNAlater (Ambion), quick freezing at −80°C and mechanical fragmentation. Genomic DNA 
was isolated using the Blood & Cell Culture DNA Midi Kit (Qiagen). Total RNA was 
extracted using the miRNeasy Mini Kit (Qiagen) and quality checked with an Agilent 2100 
Bioanalyzer (Agilent Technologies). DNA and RNA concentrations were quantified using a 
Nanodrop 1000 Spectrophotometer (Thermo Fisher Scientific). 
Quantitative realtime PCR (qPCR)-based MACC1, MET and HGF gene copy number and 
mRNA expression together with mutational profile for KRAS, BRAF, PIK3CA and NRAS 
were previously performed on this cohort of patients, for details see31, 32. 
Statistics 
All statistical analyses were performed with R-Bioconductor33: univariate and multivariate 
analyses were performed with the Survival package34, Receiver operating characteristic with 
ROCR35. Significance for ROC curves was evaluated with the Wilcox test.  
To statistically evaluate known clinical prognostic indicators in our patients set, we defined 
cut-off values according to the work of Fong and colleagues10. In particular, we considered 
as poor prognosis indicators the following five parameters: (i) initial disease stage = N+; (ii) 
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synchronous metastasis, or metastatic recurrence within 12 months after primary resection; 
(iii) number of metastatic nodes greater than 1; (iv) maximum liver node diameter > 50 mm; 
(v) preoperative CEA ≥ 200ng/ml. All analyses were censored at three years, so that poor 
prognosis cases were those with diagnosed recurrence within 36 months.  
To classify patients on the basis of MACC1 expression, we calculated the 5th percentile of 
the MACC1 mRNA qPCR score in the group of patients who has recurrence within three 
years. Patients with MACC1 score below the threshold were classified as low risk, the 
remaining patients as high risk. In this way, we considered that the chosen threshold should 
bring an acceptable five percent of false negatives (cases with recurrence within 36 months 
classified as low risk). To evaluate the robustness of the threshold, we performed a 
Montecarlo simulation with 10’000 iterations36 where, in each iteration, samples were 
randomly reassorted in good and poor prognosis groups and the threshold was chosen as the 
5th percentile of the random poor prognosis group. The distribution of the 10’000 random 
threshold values was significantly lower than the real threshold, indicating that, overall, true 
poor prognosis samples have higher MACC1 expression (p < 0.005). 
 
Results 
Perioperative Clinical and Molecular characteristics 
The clinical and molecular characteristics of the 64 patients whose tumor samples were used 
are described in Table 1. There were 52 males with a mean age of 66.4 years. In more than 
two thirds of the patients the primary tumor was located in the colon and had regional 
metastastic lymph nodes. Liver metastases were diagnosed synchronously in 28 (43.8%) 
patients; in the 36 metachronous patients, the mean interval free of disease was 16 months 
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(SD = 9). Most of the patients had multiple, small liver metastases.  At final pathology 
analysis, all the patients had a negative resection margin.  
Thirty-six patients (56.3%) received neoadjuvant systemic chemotherapy before liver 
resection. The chemotherapy regimen was oxaliplatin-based in 15 patients and irinotecan-
based in the remaining 20 patients; anti-VEGF monoclonal antibodies were added in 21 
patients. Forty-three patients (67.2%) received adjuvant systemic chemotherapy, oxaliplatin-
based in 20 patients and Irinotecan-based in 12; anti-VEGF monoclonal antibodies were 
added in 6 patients. Overall 23 patients (20.3%) underwent both neoadjuvant and adjuvant 
chemotherapy. 
Prognostic assessment of known clinical and molecular parameters. 
The median follow-up for disease-free patients was 33 months with 55% of the patient free 
of disease at 3 years. By univariate Cox regression analysis we evaluated prognostic 
significance of known clinical parameters associated with long-term outcome11. The analysis 
revealed significant association with poor prognosis for “Node Size” (HR = 2.741, 95% CI = 
1.27-5.914, p < 0.05) and “pre-resection CEA” (HR = 2.9, 95% CI = 1.296-6.489, p < 
0.001).  
The contribution of oncogenic mutations such as KRAS, PIK3CA, BRAF and NRAS in the 
context of primary disease37-42 is undisputed; however only recently their possible role has 
been explored in the context of metastatic disease43-45. In our 64-sample set, KRAS mutation 
was found in 21 cases and PIK3CA mutation was found in 7 cases. KRAS status showed 
significant association with DFS (HR = 2.07, 95% CI: 1.048-4.09, p < 0.05). Only two and 
three mutated cases were found for, respectively, BRAF and NRAS, which did not allow 
statistical analysis. Table 2 shows the results for all the evaluated parameters.  
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Prognostic assessment of MACC1, MET and HGF mRNA and copy number levels  
We explored the possible correlation with DFS of MACC1, MET, and HGF mRNA 
expression or gene copy variation. ROC curve analysis revealed a significant association 
between MACC1 mRNA expression, measured by quantitative real-time PCR, and DFS 
which was the most significant among the variables considered in the analysis (area under 
the curve = 0.65; p < 0.05; Fig 1). According to the ROC curve, a very low false negative 
rate for tumor recurrence is observed in correspondence of low levels of MACC1 (upper 
right part of the curve). No significant partitioning capability was observed for MACC1, 
MET and HGF gene copy variation or for MET/HGF expression, with p-values higher than 
0.1 (Supp. Fig1). 
To test the performance of MACC1 mRNA level as a prognostic classifier, we defined a 
qRT-PCR threshold (“MACC1 score” > -1.30) at which only 5% of the poor prognosis cases 
would be misclassified, thereby subdividing patients in “low-MACC1” (good prognosis; 13 
samples) and high-MACC1 (poor prognosis; 51 samples). MACC1-based prognostic 
stratification was found significant by Cox regression analysis (HR = 5.966, 95% CI: 1.426-
24.96, p = 0.0144) and Kaplan-Meier with log-rank test, which highlighted a one year-
longer DFS for low-MACC1 patients (median DFS = 32.63 vs. 20.23 months, p < 0.01; 
Figure 2A). Interestingly, the percentage of relapses within 36 months was substantially 
lower in low-MACC1 (15.4%) vs. high-MACC1 patients (64.7%; Fischer exact test p-value 
< 0.005; Figure 2B).  
MACC1 is an independent prognostic classifier. 
In the sample set analysed, four  prognostic parameters were statistically significant in 
univariate analysis: “MACC1”, “KRAS”, “preoperative CEA levels” and “Node Size”. To 
evaluate possible dependencies between these parameters, we carried out multivariate Cox 
regression analysis. The results, shown in Table 3 (Figure 3), confirmed “MACC1” as an 
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independent predictor of DFS. Interestingly, only two other variables (“Node Size” and 
“preoperative CEA”) remained significant in this analysis.  
We then assessed the distribution of all variables considered for multivariate analysis within 
the high-MACC1 and low-MACC1 subgroups. “Node Size” and “Preop-CEA” values were 
evenly distributed across MACC1 expression values. Interestingly instead, KRAS mutation 
was found to be more frequent in high-MACC1 cases (19/51, 37.3%) than in low-MACC1 
cases (2/13, 15.4%). Although not statistically significant (Fisher exact test p-value = 
0.1912), this correlation between KRAS mutation and high MACC1 may explain the loss of 
prognostic significance for KRAS mutation in multivariate analysis. 
Finally, we tentatively stratified patients taking into account the three parameters found to 
be independently significant in multivariate analysis: “NodeSize”, “Preop-CEA” and 
MACC1. A score was calculated as cumulative recurrence risk index, ranging therefore from 
0, for patients with no positives (lowest risk), to 3, for patients positive to all parameters. 
Interestingly, as shown in Figure 4, cases with an index of zero had an extremely low 
recurrence risk, while 7 out of 10 cases with index = 2 had recurrence within one year, None 
of the patients had a score of 3. 
 
Discussion 
MACC1 has been originally identified through genome-wide expression analyses, 
comparing primary and metastatic colon cancers18. Based on these, MACC1 over expression 
was proposed as an independent prognostic indicator of metastatic dissemination, which 
correlates with enhanced invasion and aggressiveness of the primary tumors14-18. Macc1 is 
known to promote transcription of the MET gene, thereby activating the HGF/Met axis and 
promoting tumor cell motility and invasion18; recently a more complex regulatory network 
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involving downregulation of miRNAs targeting both MACC1 -namely miR-14346- and MET 
–namely miR-128- has been implicated in the promotion of colon cancer cell invasion.  
However, we previously observed that pharmacological blockade of Met does not abrogate 
in vivo growth of metastatic colorectal cancer, while in vivo blockade of MACC1 was fount 
to inhibits metastatic dissemination in mouse models, suggesting that MACC1 may operate 
through additional pathways and mechanisms31, 47. Based on these findings, a robust 
rationale emerges clearly, implicating MACC1 in the metastatization progress from primary 
tumor.  
In this paper we investigate, for the first time, the prognostic impact of MACC1 expression 
in metastatic colorectal cancer after curative liver resection: high MACC1 levels are 
associated with significantly higher rates of recurrence within 36 months.  
The observation that a player involved bona fide in the invasive process of primary tumor is 
prognostic also within the context of metastatic disease is not obvious, and deserves further 
discussion. A potential explanation for this apparent paradox is threefold: (i) the increased 
invasive potential due to MACC1 overexpression could underlie pre-existent and diffused 
patterns of undetectable micro-metastatic dissemination of the primary lesion, so that 
surgery of liver metastases only apparently eradicates the disease; (ii) the metastases 
overexpressing MACC1 could be locally more invasive per se, thus increasing the risk of 
secondary micrometastasization before resection; (iii) beside its pro-invasive properties, 
MACC1 could also elicit additional effects on growth or survival of cancer cells. Indeed, we 
and others have proposed that further MACC1-activity mediators could be hypothesized 
beside Met31, 49. MACC1 expression is endowed with a stronger prognostic power than MET 
mRNA, which would argue against the idea that MET is the sole mediator of MACC1 
biological effects, in line with previous findings16, 18, 26. Further studies are needed to clarify 
this issue, which will involve both high-throughput expression analyses and functional 
 
 
 
11 
validation experiments to identify and test the biological relevance of other, MET-
independent MACC1 targets within the context of CRC progression.  
The potential clinical implications of MACC1 as independent prognostic factor of 
recurrence are based on its ability to identify two classes of recurrence risk among the 
patients undergone curative liver resection for colorectal metastases. In Europe, 
perioperative chemotherapy is a common approach even for patients with resectable 
colorectal metastases. Recently, a panel of experts has recommended that most patients with 
resectable colorectal liver metastases should receive perioperative chemotherapy4. 
Particularly, systemic chemotherapy after liver resection of colorectal metastasis, is offered 
to all the patients fit to treatment. However, a pooled analysis of adjuvant studies has 
showed only non-significant 10% increase in disease-free survival with a grade 3-4 toxicity 
in about 30% of the treated patients5. Overall, the benefit of adjuvant treatment seems 
extremely limited, which calls for confining its use to high risk patients’ subpopulations, 
thus preventing useless over treatment and associated toxicities. As a side effect, significant 
treatment-associated expenses could be spared, which as a whole would improve cost-
effectiveness of the therapeutic approach50. In the present study, low-MACC1, good 
prognosis patients had a significantly lower recurrence rate (2 out of 13; 15.4%) than  high-
MACC1, poor prognosis patients (35 out of 51; 68.6%; p=0.01). Moreover, the prognostic 
power of MACC1 expression seems to be unrelated to adjuvant therapy (HR = 6.5 in 
patients treated with Ajuvant therapy, HR = 4.3 for patients not threated) so that a relevant 
contribution of MACC1 levels in predicting treatment efficacy is unlikely. 
This reinforces the notion that MACC1 is a pure prognostic indicator that could be exploited 
to inform rational therapeutic decisions following surgical intervention. If validated in larger 
cohorts of patients, our results could justify a MACC1-based categorization of patients, to 
spare good prognosis patients from useless adjuvant treatment. The technique used to 
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measure MACC1 mRNA levels, i.e. quantitative realtime PCR, is a well established 
procedure that has successfully been employed for prognostic assessment in various types of 
cancer, including colorectal cancer44, which facilitates further assessments and extensive 
clinical validation. Moreover, the strong independence of MACC1 from other clinical 
parameters of prognostic value, i.e. “NodeSize” and “Preop-CEA”, holds promise for further 
integration and risk stratification scores.  
Interestingly, the negative prognostic impact of KRAS mutation on liver metastatic 
colorectal cancer45 is confirmed in our data. However, its prognostic significance is lost in 
multivariate analysis, when MACC1 is included. This finding, together with the fact that 
KRAS mutation is more frequent in high-MACC1 cases, highlights possible cooperation 
between the two oncogenes and, if further validated in larger cohorts of patients, could 
increase the interest for MACC1 assessment in clinical practice.  
In conclusion, if confirmed, the results presented here could pave the way for the inclusion 
of MACC1 expression analysis in a multiparametric score (including molecular, clinical and 
pathological features) that could help the clinician in assigning aggressive, mild or even 
none adjuvant regimens to resected patients, depending on their relapse risk, even in the 
context of metastatic diseases. We are planning to validate both the prognostic relevance of 
MACC1 and its integration with clinical prognostic factors in a larger cohort of patients 
undergoing curative liver resection of colorectal cancer metastases. 
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Table 1. Perioperative clinical and molecular characteristics of the 74 patients 
Clinical characteristics    Number of patients 
Age (years)*   66.4 (8.9) 
Sex (Male)   52 (81.3) 
CEA§   39.0 (114.4) 
Primary tumour Site   
  Colon 45 (70.9) 
  Rectum 19 
Primary tumour N stage#   
  Positive 43 (67.2) 
  Negative 21 
Liver metastases     
 Synchronous$   28 (43.8) 
 Number*  3.7 (4.6) 
  Single 28 (43.8) 
  Multiple 36 
 Size*  33.6 (sd 20.1) 
  > 5 cm 10 (15.6) 
  ≤5 cm 52 
  Not Available 1 
 Neoadjuvant Chemotherapy  36 (56.8%) 
  Oxaliplatin-based 16 
  Irinotecan-based 20 
  Targeted Therapy 21 
 Adjuvant chemotherapy  43 (67.2%) 
  Oxaliplatin-based 31 
  Irinotecan-based 12 
  Targeted Therapy 6 
 
Values in parentheses are percentages unless indicated otherwise. * Values are mean (s.d.) 
§ Serum carcinoembryonic antigen (CEA) levels (ng/ml) before hepatectomy. # N: lymph 
node status of the primary tumour. $ At diagnosis.
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Table 2. Univariate Cox regression models of disease free survival for clinical parameters 
Parameter Hazard Ratio Lower .95 Upper .95 P.value 
N Stage 2.245 0.9779 5.155 0.0565 
Early MTS 0.7556 0.3661 1.559 0.448 
NodeNumber 1.079 0.548 2.125 0.825 
NodeSize 2.741 1.27 5.914 0.0102* 
Preop CEA 2.9 1.296 6.489 0.00959** 
NeoAdjuvant 1.357 0.6709 2.744 0.396 
Adjuvant 0.7693 0.3636 1.628 0.493 
KRAS 2.07 1.048 4.09 0.0362* 
PIK3CA 2.049 0.7885 5.325 0.141 
 
*p<0.05 ; **p<0.01 
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Table 3. Multivariate Cox regression models of disease free survival for molecular 
parameters 
Parameter Hazard Ratio Lower .95 Upper .95 P.value 
NodeSize 3.4392 1.5634 7.566 0.002135** 
Preop CEA 15.1490 3.0906 74.255 0.000805*** 
MACC1 7.2739 1.6584 31.905 0.008525** 
KRAS 1.5843 0.7943 3.160 0.191436 
 
**p<0.01; *p<0.05
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Figure Legends 
 
Figure 1. ROC curve analysis for (A) MACC1, (B) MET and (C) HGF mRNA levels 
 
Figure 2. (A) Kaplan-Meier survival analysis of low-MACC1 patients (green line) and high-
MACC1 patients (red line). (B) Contingency table displaying the fraction of disease-free or 
recurred cases within high-MACC1 and low-MACC1 samples. 
 
Figure 3. Forest plot showing HRs and 95% confidence intervals of clinical and molecular 
parameters, obtained from a multivariate Cox Regression model. 
 
Figure 4. Kaplan-Meier survival analysis of cases subdivided by a combined risk index 
calculated as the sum of “high-MACC1”, “high-preoperative-CEA” and “Node Size > 5cm”. 
Patients with no positives (green line) display the lowest recurrence risk. Patients with one 
positive (blue line) have an intermediate risk. Patients with two positives (red line) have the 
highest recurrence risk. 




